Restenosis after balloon angioplasty and stenting (BAS) remains an unsolved clinical dilemma for patients with coronary artery disease. A better understanding of the mechanisms that drive this phenomenon is likely to lead to more effective treatments. In this issue of the JCI, Ali et al. uncover a critical redox axis with the antioxidant enzyme glutathione peroxidase-1 (GPX1) at its hub and identify potential new therapeutic targets, such as ROS1 tyrosine kinase. This study represents a potential new approach to finding a treatment for BAS, with implications that may extend beyond BAS to other vasculopathies involving vascular remodeling.
展开▼
机译：球囊血管成形术和支架置入术 （BAS） 后的再狭窄仍然是冠状动脉疾病患者尚未解决的临床难题。更好地了解驱动这种现象的机制可能会导致更有效的治疗。在本期JCI中，Ali等人发现了一个关键的氧化还原轴，其中心是抗氧化酶谷胱甘肽过氧化物酶-1（GPX1），并确定了潜在的新治疗靶点，如ROS1酪氨酸激酶。这项研究代表了一种潜在的新方法来寻找 BAS 的治疗方法，其影响可能超出 BAS 扩展到其他涉及血管重塑的血管病。
展开▼
